Tolerability, pharmacokinetics and antiviral activity of rHSA/IFNα2a for the treatment of chronic hepatitis B infection
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tolerability, pharmacokinetics and antiviral activity of rHSA/IFNα2a for the treatment of chronic hepatitis B infection
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume 83, Issue 5, Pages 1056-1071
Publisher
Wiley
Online
2016-11-09
DOI
10.1111/bcp.13184
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Making a case for albumin – a highly promising drug-delivery system
- (2015) Angelica M Merlot et al. Future Medicinal Chemistry
- Optimal management of hepatitis B virus infection – EASL Special Conference
- (2015) Pietro Lampertico et al. JOURNAL OF HEPATOLOGY
- Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013
- (2015) Aparna Schweitzer et al. LANCET
- Management of hepatitis B virus infection during treatment for hepatitis B virus-related hepatocellular carcinoma
- (2015) Shoji Kubo WORLD JOURNAL OF GASTROENTEROLOGY
- EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
- (2015) JOURNAL OF HEPATOLOGY
- HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?
- (2013) Jia-Horng Kao LIVER INTERNATIONAL
- Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3
- (2012) S. Pianko et al. JOURNAL OF VIRAL HEPATITIS
- Natural history of chronic hepatitis B: what exactly has REVEAL Revealed?
- (2012) Uchenna H Iloeje et al. LIVER INTERNATIONAL
- Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity
- (2012) J.J. Ott et al. VACCINE
- Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-α in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 2 or 3
- (2010) David R. Nelson et al. GASTROENTEROLOGY
- Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy*)
- (2010) Philippe Halfon et al. JOURNAL OF MEDICAL VIROLOGY
- Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C
- (2009) Vinod K. Rustgi CURRENT MEDICAL RESEARCH AND OPINION
- Factors That Predict Response of Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B to Peginterferon-Alfa
- (2009) Erik H.C.J. Buster et al. GASTROENTEROLOGY
- Anti-Hepatitis B Virus Activity and Mechanisms of Recombinant Human Serum Albumin-Interferon-α-2b Fusion Protein in vitro and in vivo
- (2009) Xu Bingfa et al. PHARMACOLOGY
- Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C
- (2008) Stefan Zeuzem et al. HEPATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now